Skip to main content

Table 1 Factors associated with death in a cohort of HIV-infected patients in French Guiana 19922008: multivariate Cox modeling

From: HIV patients dying on anti-tuberculosis treatment: are undiagnosed infections still a problem in French Guiana?

 

Time at risk (person-years)

Incidence rate

Adjusted hazard ratio

95% confidence interval

P

Age < 30 years

1797

2.28

1

  

Age [30-40 years]

2998

4.16

1.69

1.10-2.59

0.01

Age [40-60 years]

4116

3.76

1. 47

1.14-2.64

0.009

Age > 60

696

7

6.16

3.70-10.27

0.000

1991-1996 time-period

773

14.6

5.29

3.56-7.87

0.000

1997-2002 time-period

4182

4.47

2.68

1.96-3.68

0.000

2003-2008 time-period

4652

1.5

1

  

CD8 < first quartile (643/mm3)

2156

7.2

1.77

1.37-2.28

0.000

CD8 >=643 per mm3

6716

2.09

   

CD4 < 50

645

23.25

36.02

15.41-84.20

0.000

CD4 [50-200]

1809

5.14

12.34

5.32-28.63

0.000

CD4 [200-500]

4387

1.18

4.33

1.86-10.11

0.001

CD4 > 500

2167

0.27

1

  

Antiretroviral treatment

4938

1.47

.30

0.22-0.40

0.000

No antiretroviral treatment

4670

6.35

   

Tuberculosis (any location)

62

36.69

5.37

2.29-12.58

0.000

No tuberculosis

9546

3.63

   

Tuberculosis treatment

238

24.3

2.44

1.65-3.60

0.000

No tuberculosis treatment

9370

3.32

   

Interaction confirmed tuberculosis and tuberculosis treatment

  

0.20

0.07-0.60

0.004

Histoplasmosis

105

35.89

1.97

1.19-3.26

0.008

No histoplasmosis

9502

3.49

   

Histoplasmosis treatment

289

7.2

.79

0.37-1.57

0.50

No histoplasmosis treatment

9319

3.74

   

Interaction confirmed histoplasmosis and antifungal treatment

  

1.09

0.37-3.15

0.86

Pneumocystosis

70

17.06

4.18

1.48-11.80

0.007

No pneumocystosis

9538

3.75

   

Cotrimoxazole

2230

6.77

1.44

1.08-193

0.01

No cotrimoxazole

7378

2.96

   

Interaction pneumocystosis cotrimoxazole

  

0.13

0.03-0.49

0.003

Toxoplasmosis

86

44.14

3.52

1.97-6.28

0.000

No toxoplasmosis

9522

3.48